Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan 18;8(2):261-265.
doi: 10.1021/acsmedchemlett.6b00487. eCollection 2017 Feb 9.

Novel 2-Substituted 7-Azaindole and 7-Azaindazole Analogues as Potential Antiviral Agents for the Treatment of Influenza

Affiliations

Novel 2-Substituted 7-Azaindole and 7-Azaindazole Analogues as Potential Antiviral Agents for the Treatment of Influenza

Upul K Bandarage et al. ACS Med Chem Lett. .

Abstract

JNJ-63623872 (2) is a first-in-class, orally bioavailable compound that offers significant potential for the treatment of pandemic and seasonal influenza. Early lead optimization efforts in our 7-azaindole series focused on 1,3-diaminocyclohexyl amide and urea substitutions on the pyrimidine-7-azaindole motif. In this work, we explored two strategies to eliminate observed aldehyde oxidase (AO)-mediated metabolism at the 2-position of these 7-azaindole analogues. Substitution at the 2-position of the azaindole ring generated somewhat less potent analogues, but reduced AO-mediated metabolism. Incorporation of a ring nitrogen generated 7-azaindazole analogues that were equipotent to the parent 2-H-7-azaindole, but surprisingly, did not appear to improve AO-mediated metabolism. Overall, we identified multiple 2-substituted 7-azaindole analogues with enhanced AO stability and we present data for one such compound (12) that demonstrate a favorable oral pharmacokinetic profile in rodents. These analogues have the potential to be further developed as anti-influenza agents for the treatment of influenza.

Keywords: 7-azaindole; Influenza; PB2 subunit; aldehyde oxidase; metabolic stability.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
Inhibitors of influenza virus: NA inhibitor oseltamivir (1), 2, and azaindole screening hit 3.
Figure 2
Figure 2
Potent anti-influenza compounds and primary metabolite (5).
Scheme 1
Scheme 1. Synthesis of Compound 12
Reagents and conditions: (a) HC≡CHCH2OTHP, Pd(PPh3)2Cl2, CuI, THF, Et3N, 80 °C, 1 h, 82%; (b) t-BuOK, THF, 85 °C, 2 h, 64%; (c) NIS, DMF, DCM, RT, 1 h, 99%;(d) i. NaH, THF, RT, 30 min; ii. PhSO2Cl, 1 h, 97%; (e) bis(pinacolato)diboron, PdCl2(dppf)·DCM, KOAc, DMF, 85 °C, 3 h, 60%; (f) i. 14, Pd(PPh3)4, THF, aq. Na2CO3, 80 °C, 18 h; ii. TFA, MeOH, H2O, 1 h, 80%; (g) 4 N HCl, 1,4-dioxane, CH3CN, 65 °C, 1 h, 68%.
Scheme 2
Scheme 2. Synthesis of Compound 14
Reagents and conditions: (a) i. ethyl (1R,3S)-3-aminocyclohexanecarboxylate, THF, reflux, 18 h, 92%; ii. LiOH, THF, water, 95 °C, 1 h, 97%; (b) DPPA, Et3N, pyrrolidine, Et3N, THF, RT, 85 °C, 2 h, 85%.
Scheme 3
Scheme 3. Synthesis of Compounds 19, 20, and 21
Reagents and conditions: (a) (COCl)2, DMSO, Et3N,-78 °C, 2 h, 86%; (b) i. Na2HPO4, NaClO2, 2-butene, t-BuOH, RT, 18 h, 88% ii. 4 N HCl, 1,4-dioxane, CH3CN, 65 °C, 1 h, 68%; (c) i. NH2OH, EtOH, reflux, 3 h; ii. 4 N HCl, 1,4-dioxane, CH3CN, 65 °C, 1 h, 68%; (d) i. CH3MgBr, THF, RT, 1 h; ii. 4 N HCl, 1,4-dioxane, CH3CN, 65 °C, 1 h, 68%.
Scheme 4
Scheme 4. Synthesis of Compound 23
Reagents and conditions: (a) NIS, DCM, RT, 100 °C, 2 h, 80%; (b) trityl chloride, K2CO3, DMF, RT, 18 h, 81%; (c) bis(pinacolato)diboron, PdCl2(dppf).DCM, KOAc, DMF, 95 °C, 1 h, 100%; (d) 14, Pd2(dba)3, X-Phos, K3PO4, 2-methylTHF, H2O, 120 °C, 2 h, 48%; (e) Et3SiH, 30 mol-equiv of TFA, DCM, RT, 30 min, 92%.
Figure 3
Figure 3
(A) X-ray crystal structure of 12 bound to PB2 (PDB ID: 5BUH). (B) X-ray crystal structure of 16 bound to PB2 (PBD ID: 5F79).

References

    1. Fiore A. E.; Shay D. K.; Broder K.; Iskander J. K.; Uyeki T. M.; et al. Prevention and control of influenza: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2008, 57, 1–60. - PubMed
    1. Li Q.; Zhou L.; Zhou M.; Chen Z.; Li F.; Wu H.; Xiang N.; Chen E.; Tang F.; Wang D.; Meng L.; Hong Z.; Tu W.; Cao Y.; Li L.; Ding F.; Liu B.; Wang M.; Xie R.; Gao R.; Li X.; Bai T.; Zou S.; He J.; Hu J.; Xu Y.; Chai C.; Wang S.; Gao Y.; Jin L.; Zhang Y.; Luo H.; Yu H.; Gao L.; Pang X.; Liu G.; Shu Y.; Yang W.; Uyeki T. M.; Wang Y.; Wu F.; Feng Z. Epidemiology of the avian influenza A (H7N9) outbreak in China. N. Engl. J. Med. 2014, 370, 520–532. 10.1056/NEJMoa1304617. - DOI - PMC - PubMed
    1. Lamb R. A.; Krug R. M.. Orthomyxoviridae: The viruses and their replication. In Fields Virology, 4th ed.; Knipe D. M., Howley P. M., Eds.; Lippincott Williams & Wilkins: Philadelphia, PA, 2001; p 1487.
    1. Moscona A. Neuraminidase inhibitors for influenza. N. Engl. J. Med. 2005, 353, 1363–1373. 10.1056/NEJMra050740. - DOI - PubMed
    1. Thorlund K.; Awad T.; Boivin G.; Thabane L. Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infect. Dis. 2011, 1, 134–147. 10.1186/1471-2334-11-134. - DOI - PMC - PubMed